SMAR Daily Industry News

Institutional Buying Boosts Four Indian Pharma Stocks

Institutional investors are adding to positions in several Indian pharmaceutical companies, signalling confidence in the sector's earnings outlook and growth initiatives. Both foreign institutional investors (FIIs) and domestic institutional investors (DIIs) raised their holdings during the September quarter, highlighting a broader shift of smart money toward pharma equities amid expanding pipelines and overseas market opportunities.

Gujarat Themis Biosyn (GTBL), founded in 1981 as a joint‑sector venture, began with erythromycin production and later partnered with South Korea's Yuhan Corporation to launch commercial rifampicin. FIIs more than doubled their stake from 1.76% to 3.8%, while DIIs surged from 1.17% to 12.65% in the September quarter. In Q1 FY27 the firm posted revenue of ₹43.8 crore, up 22.1% YoY, EBITDA of ₹20.8 crore, a 49.4% rise, and PAT of ₹11.1 crore, reflecting improved margins from higher volumes.

(Opinion) The sharp DII increase suggests strong domestic confidence, possibly driven by GTBL's recent inorganic expansion. Acquisitions of Sanofi’s brands and Japan's MicroBiopharm broaden distribution and manufacturing capabilities, while new R&D, API units and a hybrid power plant aim to lower costs and carbon footprint, positioning the company for scalable growth.

Cipla Ltd, a legacy player established in 1935, saw FIIs edge up their stake from 20.20% to 20.24% and DIIs from 34.35% to 34.61% during the same period. The company continues to focus on its North America business, expecting sequential growth supported by four product launches, including three respiratory assets and a peptide candidate. Regulatory activity included a US FDA routine GMP inspection at the Verna, Goa plant classified as voluntary action indicated, and a single Form 483 observation at the New York Invagen facility, both pending corrective actions.

(Context) Cipla's modest stake changes reflect a steady institutional view rather than a speculative surge. The pending FDA corrective steps introduce regulatory risk, but the pipeline of respiratory generics and specialty launches could sustain revenue momentum, especially in the lucrative US market.

Torrent Pharmaceuticals, the flagship of the Torrent Group, recorded FIIs increasing their holding from 15.44% to 17.22% and DIIs from 9.73% to 13.37% in the September quarter. Q1 FY27 revenue jumped 55% to ₹4,921 crore, with operating EBITDA rising 61% to ₹1,664 crore and an EBITDA margin of 33.8%. The July merger of JB Chemicals with Torrent Pharma, back‑dated to 21 January 2026, expands the combined entity’s product breadth. Management plans to grow market share in key therapeutic segments, boost field force productivity, and scale the Curatio business in FY27.

(Opinion) The significant revenue and EBITDA growth, coupled with the merger, may justify the increased institutional interest. However, the expanded product portfolio could also bring integration challenges and heightened competition, factors that investors will likely monitor closely.

Rubicon Research, a specialty formulations company, saw FIIs lift their stake from 7.52% to 9.01% and DIIs from 9.43% to 15.73% over the quarter. Q1 FY27 revenue rose 52% YoY to ₹534.3 crore, while gross profit increased 46% to ₹354.3 crore. PAT, boosted by a one‑off insurance claim, climbed 96% to ₹84.8 crore from ₹43.3 crore a year earlier. The top five products contributed 39% of revenue and the top ten accounted for 55%, indicating a moderately diversified product mix.

(Context) Rubicon's strong top‑line growth and near‑doubling of profit suggest effective execution of its R&D‑driven strategy. The reliance on a limited set of products for a majority of revenue may expose the firm to concentration risk, especially if regulatory or market dynamics shift for those key offerings.

While the four companies have attracted notable institutional buying, the presence of FIIs or DIIs does not guarantee superior returns. Investors should evaluate each firm’s revenue trajectory, profit margins, debt levels, valuation multiples, R&D spend and regulatory exposure before committing capital. Institutional activity provides a useful signal, but thorough due diligence remains essential for retail investors.

Why it matters

Institutional buying highlights market confidence in these pharma firms, yet investors must assess fundamentals and risks before following the trend.

FAQ

Which company saw the largest increase in DII stake during the September quarter?
Gujarat Themis Biosyn's DII stake rose from 1.17% to 12.65%.

What was Rubicon Research's profit after tax growth year‑on‑year in Q1 FY27?
PAT increased 96% from ₹43.3 crore to ₹84.8 crore.

How did FIIs' stake in Cipla change in the September quarter?
FIIs increased their stake marginally from 20.20% to 20.24%.

What regulatory finding did the US FDA report for Cipla's Verna plant?
The plant was classified as voluntary action indicated, meaning objectionable conditions were found but no enforcement action was taken.

Source: Mint Markets. See the original source for full details.